Gene therapy studies, involving tumor modification for production of inflammatory cytokines (e.g. IL-2) to enhance tumor immunogenicity[78] as well as with IL-12-expressing DNA plasmids to slow tumor growth and stimulate a robust CTL response,[79] have also utilized the GL261 model. Here, IL2 is linked to neoplasm.